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G protein-coupled receptors (GPCRs) are involved in essentially all physiological
processes in mammals. The classical GPCR signal transduction mechanism occurs
by coupling to G protein, but it has recently been demonstrated that interaction with
β-arrestins leads to activation of pathways that are independent of the G protein
pathway. Also, it has been reported that some ligands can preferentially activate one
of these signaling pathways; being therefore called biased agonists for G protein or
β-arrestin pathways. The angiotensin II (AngII) AT1 receptor is a prototype GPCR in
the study of biased agonism due to the existence of well-known β-arrestin-biased
agonists, such as [Sar1, Ile4, Ile8]-AngII (SII), and [Sar1, D-Ala8]-AngII (TRV027). The aim
of this study was to comparatively analyze the two above mentioned β-arrestin-biased
agonists on downstream phosphorylation events and gene expression profiles. Our data
reveal that activation of AT1 receptor by each ligand led to a diversity of activation
profiles that is far broader than that expected from a simple dichotomy between
“G protein-dependent” and “β-arrestin-dependent” signaling. We observed clusters of
activation profiles common to AngII, SII, and TRV027, as well as downstream effector
activation that are unique to AngII, SII, or TRV027. Analyses of β-arrestin conformational
changes after AT1 receptor stimulation with SII or TRV027 suggests that the observed
differences could account, at least partially, for the diversity of modulated targets
observed. Our data reveal that, although the categorization “G protein-dependent”
vs. “β-arrestin-dependent” signaling can be of pharmacological relevance, broader
analyses of signaling pathways and downstream targets are necessary to generate an
accurate activation profile for a given ligand. This may bring relevant information for drug
development, as it may allow more refined comparison of drugs with similar mechanism
of action and effects, but with distinct side effects.
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Introduction
G protein coupled receptors (GPCRs) represent the largest
family of transducers of signals, with more than 800 genes
in the human genome. These receptors bear the conserved
general structure of seven alpha-helices spanning the cytoplasmic
membrane, and for this reason are also referred to as seven
transmembrane domain receptors (7TMRs) (Selbie and Hill,
1998; Katritch et al., 2013). GPCRs can be activated by a
diversity of ligands, such as small monoamines, peptides, large
proteins, and even by light in the case of opsins (Heng
et al., 2013). Although the GPCR name was given after their
classical mechanism of action that involves interaction with and
activation of heterotrimeric G proteins, it is now well accepted
that GPCRs can also interact with other effectors which in
some cases trigger G protein-independent signaling pathways
(Ferrand et al., 2005; Cattaneo et al., 2014). For instance,
although β-arrestins were classically considered to only promote
GPCR desensitization and internalization, therefore leading to
G protein signaling termination (Ferguson et al., 1996), it is
now recognized that arrestins also act as scaffolding proteins
and organize other effectors including kinases that can trigger
G protein-independent signaling pathways (Luttrell et al., 2001;
Charest and Bouvier, 2003; Beaulieu et al., 2005; Lefkowitz and
Shenoy, 2005). More recently, it has been shown that some
ligands bear the property of preferentially triggering one or
another pathway, leading to the concepts of “biased agonists” and
“functional selectivity” (Azzi et al., 2003; Lefkowitz and Shenoy,
2005; Galandrin et al., 2007; Kenakin, 2007; Drake et al., 2008;
Shukla et al., 2008; Kahsai et al., 2011; Audet and Bouvier, 2012).
The AT1 receptor is a prototype GPCR in the study of biased
agonism, and the peptide [Sar1, Ile4, Ile8]-AngII (SII) was one
of the first β-arrestin-biased ligands to be described (Holloway
et al., 2002). More recently, the company Trevena developed
additional β-arrestin-biased ligands for AT1 receptor (Violin
et al., 2010; Rajagopal et al., 2011; Monasky et al., 2013) including
the peptide [Sar1, D-Ala8]-AngII (TRV027), that is now entering
phase 2 clinical trials for the treatment of heart failure (Violin
et al., 2014). Both SII and TRV027 are described as preferentially
triggering β-arrestin-dependent signaling pathways over the Gq
pathways.
Based on such different profiles of proximal effector activation
when comparing the endogenous ligand, AngII, with β-arrestin-
biased ligands such as SII and TRV027, one could hypothesize
that downstream signaling cascades, including kinase activation
and gene transcription, may be a direct reflection of this
dichotomic activation profile. Accordingly, it could be predicted
that two β-arrestin-biased ligands would share a similar, but
distinct set of downstream signaling events when compared with
the endogenous ligands that activate both β-arrestin and Gq
as illustrated in Figure 1. To test this hypothesis, we analyzed
downstream signals at two distinct levels of the signaling
cascade; namely kinase activation and gene transcription. For
this purpose, the phosphorylation level of different kinase
substrates was assessed using a phosphorylation kinase array
profiler, whereas the downstream gene transcription effects were
monitored using PCR arrays.
Contrary to the hypothesis that β-arrestin-biased ligands
would share downstream signaling signatures that would be
distinct from that of AngII, we did not observe more similarities
between the two β-arrestin-biased agonists, SII and TRV027,
than between each of them and AngII. These results indicate
that additional differences in the signaling repertoire of the
ligands exist that cannot be captured only by their propensity
to differentially activate β-arrestin and Gq-mediated signaling.
Such differences may include the differential engagement of
other G protein subunits or additional poorly characterized
signaling pathways as well as ligand-specific conformational
rearrangements of β-arrestin that can result in different
downstream responses (Shukla et al., 2008; Zimmerman et al.,
2012). Consistent with the latter possibility, we observed distinct




SII and TRV027 were synthesized by solid phase synthesis
(Merrifield, 1963) using the Fmoc strategy as described
before (Fields and Noble, 1990). Briefly, the N-terminal
protecting group was removed with 20% piperidine. Amino
acids were activated by HOBt/HBTU 0.45M and couplings
were carried-out in the presence of DIPEA 1.2M and cycles
of microwave irradiation. Deprotection and coupling were
monitored using the 1% TNBS test. After cleavage from the
resin with 90% TFA, peptides were purified by HPLC and the
efficiency of synthesis was evaluated by amino acid composition
analysis.
Cell Culture and Transfection
HEK293T cells were cultured in DMEM supplemented with 10%
fetal bovine serum, 100U/ml penicillin/streptomycin, at 37◦C in
5% CO2. Cells were seeded in 10-cm dishes, and 48 hours before
the experiments were transiently transfected with AT1 receptor
using the calcium phosphate method (Gether et al., 1993). For
BRET experiments, transient transfections were performed using
polyethylenimine (PEI; 25 kDa linear; Polysciences, Warrington,
PA, USA) at a ratio of 3:1 PEI/DNA, where 5µg of AT1 receptor
and 100 ng of RlucII-βarr1-GFP10 or RlucII-βarr2-GFP10 were
cotransfected. The total amount of DNA transfected in each
plate was adjusted to 10µg with salmon sperm DNA (Invitrogen,
Carlsbad, CA, USA).
Kinase Phosphorylation Array and Quantitative
Analysis
The kinase phosphorylation array (Human Phospho-Kinase
Array, Proteome Profiler, R&D Systems, Minneapolis, MN, USA)
was used as described before (Souza and Costa-Neto, 2012).
Briefly, AT1-transfected HEK293T cells were incubated for 16 h
in serum-free DMEM prior to stimulation for 10min with AngII
100 nM, SII 30µM, TRV027 100 nM, or with vehicle as control.
Agonist concentrations were chosen based on their differences
in affinities, where SII has lower affinity as compared to AngII
and TRV027. Cells were then rinsed, lysed with Lysis Buffer 6
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FIGURE 1 | Schematic representation of (A) a reference agonist and (B) the hypothesis of downstream transduction of a “biased message” after
receptor activation by a biased agonist. AngII, angiotensin II; SII, [Sar1, Ile4, Ile8]-AngII; TRV, TRV027 ([Sar1, D-Ala8]-AngII).
(R&D Systems) and mixed for 30min at 4◦C. The lysates were
clarified by centrifugation at 14,000 × g for 5min at 4◦C, and
300µg of total protein from the lysates was incubated with a
pre-blottedmembrane array. After lysates were incubated, Chemi
Reagent Mix (R&D Systems) was added to the phospho-kinase
array membranes and the chemiluminescent signal was captured
by ImageQuant 350 (GE Healthcare, Piscataway, NJ, USA). Data
were generated from 3 independent experiments. For the analysis
of the phosphorylation level, membranes were scanned and
processed using ImageJ software (Schneider et al., 2012). The
intensities of the spots were quantified and the levels of positive
and negative controls were used to set the minimal and maximal
intensity levels. For the analysis, only spots with intensity 2-
fold higher than background in at least one experiment were
considered.
PCR Array and Quantitative Analysis
Total RNA was extracted from HEK293T cells transiently
expressing the AT1 receptor and stimulated with AngII
100 nM, SII 30µM, TRV027 100 nM or vehicle for 6 h.
Agonist concentrations were chosen based on their differences
in affinities, where SII has lower affinity as compared to
AngII and TRV027. After that, cDNAs were synthesized
from 1µg of total RNA using the RT2 First Strand Kit
(Qiagen, Hilden, Germany). We used the RT2 Profiler PCR
Array (Human GPCR Signaling PathwayFinder, Qiagen, Hilden,
Germany) to simultaneously evaluate the mRNA levels of
84 genes following stimulation with the above-mentioned
ligands, following manufacturer’s recommended procedures
(Table S2).
For the gene expression analysis, fold-change results from
3 independent experiments of Real Time PCR experiments
were clustered using Self Organizing Tree Algorithm (Herrero
et al., 2001) implemented in MeV software (Saeed et al.,
2003). For this analysis, we considered only genes with a fold-
change of ±2.0 in at least one of the experimental conditions
assayed.
BRET Assay
HEK293T cells transiently expressing the AT1 receptor and
RlucII-βarr1-GFP10 or RlucII-βarr2-GFP10 were washed once
with PBS, detached and seeded in 96-well white plates (OptiPlate;
PerkinElmer, Waltham, MA, USA). BRET was monitored in a
Victor™ X Light Luminescence microplate reader (PerkinElmer)
equipped with different donor/acceptor emission filter sets, after
addition of 5µM coelenterazine-400A (Biotium, Hayward, CA,
USA) to the cells. BRET signals were derived from the emission
detected with the energy acceptor filter (515 ± 15 nm) divided
by the emission detected using the energy donor filter (410 ±
40 nm). Five independent experiments with full concentration-
response curves and time-course assays were performed in cells
stimulated with AngII, SII or TRV027. Concentrations used for
time-course assays were AngII 100 nM, SII 30µM, and TRV027
100 nM. Agonist concentrations were chosen based on their
differences in affinities, where SII has lower affinity as compared
to AngII and TRV027.
Statistical Analyses
For phosphorylation level assays, only kinase substrates with
change in intensities of ±30% that were statistically significant
when analyzed by One-Way ANOVA test were considered to
be affected by the condition (Table S1), as described previously
(Xiao et al., 2010). Conformational change of β-arrestin in
BRET assays was analyzed by One-Way ANOVA test and
statistical significance was accepted when P < 0.05. Data graphs
were generated and statistical analyses were performed using
GraphPad software (GraphPad, San Diego, CA).
Results
Activation of the AT1 Receptor by AngII, SII, or
TRV027 Reveals Unique Patterns of Kinase
Phosphorylation for the Different Ligands
We analyzed the phosphorylation pattern of 43 different kinase
substrates exposed to lysates from cells transfected with AT1
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receptor and stimulated with AngII, SII, or TRV027 for 10min.
Figure 2A shows that among 43 kinase substrates analyzed, 13
were phosphorylated or dephosphorylated upon stimulation with
the above-listed ligands as compared to vehicle-treated cells
(see Table S1 for a list of all kinase substrates included in the
array as well as their phosphorylation status after stimulation
with AngII, SII, or TRV027). In some cases, we observed that
the phosphorylation pattern for some kinase substrates was
significantly modulated upon treatment with only one of the
tested ligands, AngII (e.g., Chk-2 and eNOS), or with SII (e.g.,
Akt and Fyn), or with TRV027 (e.g., p38α and STAT2). We
also found that the phosphorylation pattern of some kinase
substrates was similarly modulated by AngII and either TRV027
(e.g., p53 and c-JUN), or SII (e.g., ERK1/2); but no substrate
phosphorylation was similarly modulated by the two β-arrestin-
biased agonists TRV027 and SII, as can be seen in the Venn
diagram in Figure 2B. These results clearly indicate that the
simple β-arrestin bias of the ligand is not sufficient to explain
the different kinase substrate phosphorylation patterns between
TRV027 and SII (Figure 2C).
Activation of the AT1 Receptor by AngII, SII, or
TRV027 Reveals Unique Patterns of Gene
Expression
To analyze further downstream targets after receptor activation
by distinct ligands, we used a PCR array to analyze the
expression levels of 84 genes after stimulation with AngII,
SII, or TRV027 (see Table S2 for a list of all genes and
their mRNA levels after stimulation with the different ligands).
Similarly to what we observed with the phosphorylation kinase
array, no common patterns of expression modulation could
be correlated to the β-arrestin engagement bias (Figure 3).
Indeed, the set of modulated genes after stimulation with the
reference agonist, AngII, were not clearly distinct from the
set of modulated genes after stimulation with the β-arrestin-
biased agonists. Remarkably, we also found no strong overlap
between the sets of genes modulated by the two β-arrestin-
biased agonists. Based on the PCR array data, we generated
clusters of patterns for modulated genes. For this, we used Self-
Organizing Tree Algorithm (SOTA), an unsupervised neural
network widely used to perform hierarchical clustering of gene
expression patterns (Herrero et al., 2001). In this sense, SOTA
defines the hierarchical relationship between sets of expression
profiles based on appropriate distance functions, thus identifying
groups of genes with similar expression profiles (Herrero et al.,
2001). Finally, cluster boundaries (i.e., the total number of
clusters generated) are self-defined depending on the level of
heterogeneity of the expression data. Applying SOTA to the data
obtained here (Table S2) yielded clearly distinct patterns for each
ligand with greater similarities being observed between AngII
and either SII or TRV027 than between SII and TRV027, with
a total of five clusters being identified (Figure 3). Among the
differences between SII and TRV027, UCP1 was found to be
negativelymodulated by TRV027 while being positively regulated
by SII (Figure 3A, cluster C3), and AGTRAP, an AT1 receptor
associated protein, was negatively modulated by TRV027 but not
affected by SII (Figure 3A, cluster C5). Only two genes were
similarly modulated by SII and TRV027 (Figure 3A, cluster C2),
one of them being the negative regulator of G protein signaling,
RGS2.
As observed for the kinase phosphorylation array data, the
gene expression data indicate that the activation of the receptor
by β-arrestin-biased agonists does not lead to a similar set of
modulated genes suggesting other sources of signaling bias.
AngII, SII, and TRV027 Promote Distinct
Conformational Changes of β-Arrestins
To assess whether the differences in downstream signaling of
TRV027 and SII could result from differential conformational
rearrangements of β-arrestin as previously shown for other AT1
receptor ligands (Shukla et al., 2008; Zimmerman et al., 2012;
Gurevich and Gurevich, 2014), we used a BRET-based biosensor
that monitors the conformational rearrangement of β-arrestins
by measuring intra-molecular BRET between RLucII and GFP10
fused to the N- and C-termini of β-arrestins respectively (RlucII-
βarrestin-GFP10) (Charest et al., 2005). Using this approach, the
amplitude of BRET changes provides an indirect reflection of the
conformational rearrangement of β-arrestin upon its recruitment
to the receptor promoted by a given ligand.
To test the effect of the different AT1 receptor ligands on
the conformational changes of βarrestin-1 and -2, time-courses
of the ligand-promoted changes in BRET were monitored in
cells co-expressing the AT1 receptor and either RlucII-βarrestin1-
GFP10 or RlucII-βarrestin2-GFP10 and stimulated with AngII,
SII, or TRV027 at the same concentrations as used in the
kinase substrate phosphorylation and qPCR arrays. As shown in
Figures 4A,B, the 3 ligands induced a time-dependent decrease
in BRET for both β-arrestin-1 and -2, consistent with their ability
to promote the recruitment of the two β-arrestins to AT1 receptor
and the ensuing conformational change. However, the kinetics of
the changes was shown to be distinct for the 3 ligands, mainly
for βarrestin-1, with AngII yielding the fastest decrease followed
by TRV027 and then SII. Even more striking is the fact that
although the decreases reached the same level for AngII and
TRV027 at 15min, it was significantly higher for SII both for β-
arrestin-1 and β-arrestin-2. These data clearly point to distinct
β-arrestin conformational rearrangements upon stimulation with
the 3 ligands within the experimental time of the assay. To
reinforce these findings, we have performed concentration-
response curves (Figures 4C,D) that fully corroborate the
kinetics data. As seen in the time-course assays, differences for β-
arrestin-1 conformational changes were more pronounced then
those observed for β-arrestin-2 (Figures 4C,D).
Discussion
The results reported here show that the complexity of signaling
pathways activated by AT1 receptor, and possibly all GPCRs,
is greater than can be explained only by the bias of ligands
toward β-arrestin. Based on our findings from kinase substrate
phosphorylation and gene expression arrays (respectively,
Figures 2, 3), we hypothesize that the diversity of activated
targets in the two levels studied could be, at least partially, due
to the diversity of β-arrestin conformations that can be stabilized
after receptor stimulation by the different ligands. Such distinct
conformations would be responsible for stabilizing different
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FIGURE 2 | Analysis of 13 human kinase substrate phosphorylation
levels whose phosphorylation status changed after stimulation with
AngII, SII or TRV027. (A) Quantification of kinase substrate phosphorylation
levels in response to AngII, and two biased agonists for 10min. For clarity,
spot intensities were converted to a false color scale to facilitate the
visualization of the differences. (B) Venn diagram representing the set of
kinase substrates differentially modulated in the three experimental
conditions used. (C) Schematic representation of the obtained data, showing
that no clear biased message was observed at the level of kinase substrate
phosphorylation after stimulation with biased agonists.
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FIGURE 3 | Cluster analysis of target genes differentially
modulated by the three ligands assayed. (A) The five gene
clusters identified using the Self Organizing Tree Algorithm (Herrero
et al., 2001). Fold-changes were calculated comparing to untreated
samples and are represented on a log scale. (B) Schematic
representation of the obtained data, showing that no clear biased
message was observed at the level of gene expression modulation
after stimulation with biased agonists.
complexes that have arrestins as scaffold proteins, and therefore
would lead to distinct signaling cascades. It has been reported
that β-arrestins adopt different conformations after AT1 receptor
activation depending on the stimulus and the phosphorylation
state of the receptor (Shukla et al., 2008). Another study
showed that the distinct conformations adopted by β-arrestin,
depending on the ligand used to activate AT1 receptor, would be
responsible for stabilizing different complexes having arrestins
as scaffold proteins, and therefore would lead to distinct
signaling cascades with profound impact on physiological and
cellular processes (Zimmerman et al., 2012). Here, kinetic
conformational assays suggest that SII and TRV027 might induce
different conformations of both arrestins depending on the time
of stimulation, where a clearer difference was observed for β-
arrestin-1 (see Figures 4A,B). It is interesting to note that β-
arrestin-2 is commonly reported as the main arrestin involved
in AT1 receptor signaling (Hunton et al., 2005; Rajagopal et al.,
2006; Ahn et al., 2009), while here we have observed a more
prominent conformational change for β-arrestin-1. We cannot
exclude that the observed effects could result in part from
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FIGURE 4 | Analyses of β-arrestin-1 and -2 conformational changes
after stimulation with the three ligands assayed. Kinetics of
conformational changes for β-arrestin-1 (A) and β-arrestin-2 (B) were
evaluated using a fixed concentration of each ligand, the same
concentrations used in the kinase phosphorylation array and the PCR array.
Concentration-response curves were performed after 10min stimulation and
conformational changes were analyzed for β-arrestin-1 (C) and 2 (D).
One-Way ANOVA, p = 0.05: (#) AngII vs. SII; ($) AngII vs. TRV; (8) SII vs.
TRV; (n.s.) non-significant. One-Way ANOVA was performed using the area
under the curve (A,B) or the curve bottom plateaus (C,D).
different on-rates or off-rates of the ligands. For instance, despite
AngII and TRV027 having similar affinities, the observed effects
may result from a combination of distinct on- and off-rates,
which in turn could lead to different kinetics of β-arrestin
conformational changes. Considering the complexity of the
cellular environment and longer exposition periods in some
situations, we believe that such different sets of conformations
may account, at least partially, for the diversity of responses we
found in this study as shown in Figures 2, 3.
Another possible explanation for our results that cannot be
ruled out is that activation of the AT1 receptor by the studied
ligands may comprise other unknown effectors. If this is the case,
one could speculate that two β-arrestin-biased agonists such as
SII and TRV027, despite leading to a preferential coupling to
arrestins, might induce coupling to distinct “third” and “fourth”
effectors, therefore introducing a diversification in the signaling
pathways.
It has been shown that AngII and SII are able to activate many
subtypes of G proteins, namely Gi1, Gi2, Gi3, GoA, GoB, Gq, G11,
and G13, to different extents after activation of AT1 receptor,
which account for different signaling outputs of the ERK1/2
pathway (Sauliere et al., 2012). Also, AT1 receptor is described to
trigger several signaling pathways such as PI3K/Akt, JAK/STAT,
transactivation of receptor tyrosine kinases such as EGFR and
activation of non-receptor tyrosine kinases such as Src, Pyk2, and
FAKs (Marrero et al., 1997; Tang et al., 2000; Jiang et al., 2007;
Costa-Neto et al., 2014). As it is still necessary to evaluate how
and to what extent biased ligands may differentially activate the
diversity of G protein subunits and regulate the aforementioned
pathways, we speculate that it could account, at least partially,
for the different profiles of kinase substrate phosphorylation and
gene expression levels reported in this study.
While such remarks surely deserve further analyses, we
believe that our data unveil the extreme complexity of signaling
cascades that can be modulated, even after activation by
supposedly “more selective” agonists. This observation denotes
no demerit to the concept of biased agonism, which we believe
is of extreme importance to development of future drugs, but
rather highlights the need for thorough and comprehensive
analyses when characterizing novel ligands and signaling
pathways.
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